| Use of Recombinant Human Hyaluronidase to Accelerate Rapid Insulin Analog Absorption: Experience with Subcutaneous Injection and Continuous Infusion. | |
| | |
MedLine Citation:
|
PMID: 22138081 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Objective: To review clinical studies using recombinant human hyaluronidase (rHuPH20) to increase insulin dispersion and accelerate its absorption.Methods: Ten clinical studies are reviewed.Results: In 4 euglycemic clamp studies, rHuPH20 coinjection consistently accelerated insulin absorption, providing twice the insulin exposure in the first hour, greater and earlier peak exposure, and half the exposure beyond two hours following injection. Insulin action profiles were similarly accelerated with a 15-20 minute faster onset of insulin action and a 45 minute shorter duration of action for each of the three commercial rapid-acting insulin analogs. rHuPH20 coadministration accelerated insulin absorption and action over infusion set life when delivered by pump. rHuPH20 coadministration reduced the inconsistency of insulin absorption and action profiles due to three processes: reproducibility of identical injections, differences in insulin dose, and over infusion site life. This more consistent ultrafast profile consistently reduced hyperglycemic excursions both when injected immediately preceding liquid test meals and in bolus infusions immediately before solid test meals. rHuPH20 facilitated insulin administration has been well tolerated with a safety and tolerability comparable to the comparator insulin alone.Conclusions: rHuPH20 meaningfully accelerates insulin action profiles with an extent that is comparable to the difference between rapid analog profiles and those of regular insulin. Studies are currently underway to characterize the effect on diabetes management endpoints, including A1C, blood glucose, and hyperglycemia rates, of analog insulins coformulated with rHuPH20 for the management of both type-1 and type-2 diabetes. |
| | |
Authors:
|
Daniel E Vaughn; Douglas B Muchmore |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-12-2 |
Journal Detail:
|
Title: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists Volume: - ISSN: 1934-2403 ISO Abbreviation: - Publication Date: 2011 Dec |
Date Detail:
|
Created Date: 2011-12-5 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9607439 Medline TA: Endocr Pract Country: - |
Other Details:
|
Languages: ENG Pagination: 1-26 Citation Subset: - |
Affiliation:
|
Halozyme Therapeutics, Inc. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Repairing a broken heart with hormone replacement therapy: Case report of cardiogenic shock due to u...
Next Document: Immunogenicity of Lactobacillus-expressing VP2 and VP3 of the infectious pancreatic necrosis virus (...